Guided Therapeutics, Inc. GTHP
0.10 USD -0.03 (-23.08%)
Nov 4, 2026, 3:09 PM EST
0.10 Day range 0.13
0.10 52-week range 0.54
- YTD
- -81.48%
- 1 year
- -62.96%
- Market cap
- 9.65M
- EPS (ttm)
- -0.04
- YTD return
- -81.48%
- 1-year return
- -62.96%
- Volume
- 252.64K
- Avg volume
- 31.22K
- Open
- 0.12
- Previous close
- 0.13
- Day's range
- 0.10 – 0.13
- 52-week range
- 0.10 – 0.54
1Y -0.1700 (-62.96%)
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.01 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.01 | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -0.01 | — | — |
| Mar 28, 2024 | Dec 1, 2023 | 0.00 | 0.00 | — | — |
| Aug 18, 2021 | Jun 1, 2021 | 0.00 | -0.09 | — | — |
| Jul 7, 2020 | Mar 1, 2020 | 0.00 | 0.04 | — | — |
News
Guided Therapeutics Provides Update on its Cervical Cancer Screening Study with Türkiye's Ministry of Health 
Guided Therapeutics Inc. (OTCMKTS:GTHP) Shares Shorted: Short Interest Up 55.0% in September 
Guided Therapeutics Reaches Collaborative Agreement with Türkiye's Ministry of Health to Become Primary Screening Test for Cervical Cancer 
Guided Therapeutics Receives $80,000 Payment as Fourth Installment of $700,000 Purchase Order with Chinese Distributor 
Guided Therapeutics Receives $80,000 Payment as Fourth Installment of $700,000 Purchase Order with Chinese Distributor 
Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA 
Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA 
Haemonetics (NYSE:HAE) vs. Guided Therapeutics (OTCMKTS:GTHP) Head to Head Review 
Guided Therapeutics Provides Updates on FDA Application Study Results, 2025 Earnings Increase and Successful Warrant Offering 
Guided Therapeutics (OTCMKTS:GTHP) Shares Down 12.7% – Time to Sell?
Your note
Sign in to keep a note on GTHP — it syncs with the Stock Master app.